As of 2023, the treatment success rate for patients treated for extensively drug-resistant tuberculosis (XDR-TB) in the UK stood at 48%. Forecast data for 2024 to 2028 shows a steady year-on-year increase: 50% in 2024, 52% in 2025, 54% in 2026, 55% in 2027, and 57% in 2028. This represents a continuous improvement in treatment outcomes with a Compound Annual Growth Rate (CAGR) of approximately 4% per year over these five years.
Looking ahead, trends to watch include the impact of emerging treatment protocols, advancements in medical research, and accessibility to healthcare services. The success of new drug therapies and potential policy changes will play a crucial role in these developments.
